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Background: Fluralaner, a new molecular entity of the isoxazoline class, has potent insecticidal and acaricidal
activity and can be safely administered orally to dogs.
Methods: A randomized, investigator-blinded, multi-centered field study compared the flea- and tick-control
efficacy for dogs over a 12-week period with either a single oral dose of Bravecto™ (fluralaner) formulated as a
chewable tablet or with three sequential topical Frontline™ (fipronil) treatments. Individual dogs were the
experimental unit for ticks and households were the experimental unit for fleas. A total of 108 tick-infested dogs
were treated with Bravecto™ (fluralaner) and 54 tick-infested dogs were treated with Frontline™ (fipronil). Dogs in
115 flea-infested households received Bravecto™ (fluralaner) and dogs in 61 flea-infested households received
Frontline™ (fipronil). Flea and tick counts were conducted on all dogs at weeks 2, 4, 8, and 12 following initial
treatment and efficacy was calculated as the mean percent reduction in tick or flea count at each time point
compared with the mean pretreatment initiation count for each treatment group. Additionally, the percentages of
tick-free and flea-free households were determined.
Results: At weeks 2, 4, 8, and 12, Bravecto™ (fluralaner) flea-control efficacy in treated households was 99.2%, 99.8%,
99.8%, and 99.9% respectively, while Frontline™ (fipronil) efficacy was 94.1%, 93.0%, 96.0%, and 97.3%,
respectively. Bravecto™ (fluralaner) tick-control efficacy on treated dogs at weeks 2, 4, 8, and 12 was 99.9%, 99.9%,
99.7%, and 100%, respectively, and Frontline™ (fipronil) tick efficacy was 97.6%, 93.8%, 100%, and 100%, respectively.
Of dogs showing clinical flea allergy dermatitis (FAD) signs at the study start, 85.7% in the Bravecto™
(fluralaner)-treated group and 55.6% in the Frontline™ (fipronil)-treated group were evaluated at each time point as
showing no clinical signs of FAD until study completion.
Conclusions: Bravecto™ (fluralaner) administered once orally to dogs in a chewable tablet was highly effective for
12 weeks against fleas and ticks on privately-owned dogs and was significantly non-inferior (ticks) and superior
(fleas) in comparison with topical Frontline™ (fipronil) administered 3 times sequentially.
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New and effective treatments of companion animal ecto-
parasite infestations are important because these parasites
can become tolerant to existing treatment options and
have the potential to develop resistance [1]. Veterinarians
and animal owners are also looking for more effective and
longer lasting treatments to include in their ectoparasite
control protocols. They have concerns about the irritation
and injury caused directly by fleas and ticks and the risks
these parasites introduce as infectious-disease vectors.
Additionally, poor owner compliance is a concern with
current monthly ectoparasite control retreatment rec-
ommendations [2].
Fluralaner is a member of the isoxazoline class, a novel
class of antiparasitic drugs representing safe and effective
new acaricidal and insecticidal products for management
of ectoparasitic infestations on dogs and cats [3]. Fluralaner
has been proven to have potent efficacy against ectopara-
sites and to be safe for oral administration to dogs [4].
In vitro testing determined that fluralaner is a highly potent
arthropod-specific GABA-gated chloride channel inhibitor,
with a less potent, but still significant, inhibitory activity
on arthropod glutamate-gated chloride channels and its
receptor binding was 5–236 fold better than fipronil on
arthropod GABA-gated chloride channels [5]. This receptor
potency difference could translate into improved efficacy
for fluralaner over fipronil for ectoparasite control under
field conditions.
This study presents results of a rigorous, Good Clinical
Practice (GCP) compliant, blinded field study comparing
Bravecto™ (fluralaner) with a positive control (fipronil)
under typical veterinary practice conditions. This study
evaluated whether Bravecto™ (fluralaner) is statistically
at least as effective (non-inferiority analysis) as the positive
control treatment.
Methods
This was a multicenter, randomized, field efficacy study
conducted at veterinary practices in Germany, France, and
Spain, which enrolled privately-owned dogs of any breed
or gender. The study started in August 2011 and was fin-
ished in February 2012. The veterinarians who performed
clinical assessments and parasite counts were blinded to
the treatment allocation of the dogs. The study design
used the individual dog as the experimental unit for
statistical analysis of tick infestations and the household
as the experimental unit for analysis of flea infestations.
For enrollment in the study, dogs had to have either a
visible flea or tick infestation (or both) on initial examin-
ation, with observation of at least 4 individual ectoparasites.
The dogs also needed to have an appropriate temperament
to permit required manipulations for parasite counting;
to be 10 weeks or older, at least 2 kg body weight, and
sufficiently healthy to follow the study schedule. Dogswere ineligible if the household included a severely ill
animal requiring intensive veterinary care, any dog who
had received previous ectoparasiticide treatment within the
previous 7 to 30 days depending on the expected duration
of effect of the treatment, a pregnant or lactating female
dog, more than 5 dogs, or other pet species that could har-
bor fleas and/or ticks (e.g. cats, rabbits, guinea pigs) sharing
the same resting area; if insecticide or insect growth regula-
tor had been applied in the household environment within
the previous two months; or if the dog would need to spend
substantial time at a dog sitter or animal shelter during
the study period. Dog owners were briefed on the study
protocol and required to sign an informed consent
allowing enrollment of their dog(s) in the study.
Dogs were randomly assigned, using a computer-
generated list, to receive either Bravecto™ (fluralaner,
25–56 mg/kg body weight once) or a positive control
treatment Frontline™ (fipronil, ≥6.7 mg/kg for three
sequential times) at a 2:1 fluralaner:fipronil enrollment
ratio. All dogs from the same household were treated
using the same product. A clinical examination including
a descriptive evaluation of skin and hair examinations
to document any skin lesions possibly related to FAD was
completed. An initial parasite count was performed using
the World Association for the Advancement of Veterinary
Parasitology (WAAVP) comb-counting method [6] followed
by administration of the initial treatment in the veterin-
ary hospital. All dogs that received the oral Bravecto™
(fluralaner) treatment were initially offered the opportunity
to eat the tablet voluntarily. If the tablet was refused,
the dogs were given the tablet directly into the mouth.
All dogs remained in the owner’s home and were fed
their usual diet with access to water according to their
normal routine. Grooming, bathing, and swimming were
permitted during the study, but not within 3 days prior
to a scheduled visit or within 2 days after treatment ap-
plication. Participating veterinarians and owners were
required to collect details on any suspected adverse events
throughout the study.
Regular follow-up procedures in weeks 2, 4, 8, and
12 after initial treatment included re-examinations of
dogs to document health status and any changes in
skin and hair lesions for dogs that originally presented
with FAD, followed by parasite counts. In weeks 4 and
8, dogs in the positive control group were retreated
after these procedures. Ticks were removed gently with
forceps; counted; and categorized as “live or “dead”;
ticks were subsequently sent for microscopic identification
of the species.
The percentage reduction of ticks in initially infested
dogs and percentage reduction of fleas in flea-infested
households were calculated for weeks 2, 4, 8, and 12
compared with baseline for both treatments according
to the following formula:
Table 1 Demographics of enrolled dog population
Bravecto™ (fluralaner) Frontline™ (fipronil)
n = 325 n = 154
Hair length:
Short 139 (42.8%) 66 (42.9%)
Moderate 137 (42.2%) 64 (41.6%)
Long 49 (15.1%) 24 (15.6%)
Living conditions:
Inside 84 (25.8%) 44 (28.6%)
Outside 155 (47.7%) 59 (38.3%)
Inside and outside 86 (26.5%) 51 (33.1%)
Number of dogs in the household:
n = 144 n = 70
1 76 (52.8%) 32 (45.7%)
2 19 (13.2%) 14 (20.0%)
3 11 (7.6%) 8 (11.4%)
4 11 (7.6%) 8 (11.4%)
5 27 (18.8%) 8 (11.4%)
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where xpre−treatment is the geometric mean number of live
ticks or fleas at baseline (day 0) and xpost−treatment is the
geometric mean number of live ticks or fleas post-
treatment (week 2, 4, 8, and 12).
For each visit, non-inferiority of the percentage of
parasite-free households was investigated in the Bravecto™
(fluralaner) group compared with the Frontline™ (fipronil)
group. The Farrington-Manning test [7] of non-inferiority
for the risk difference was used with a level of significance
of α=0.025 and a tolerated difference of δ=0.15.
All data for statistical analysis (SAS Institute Inc., Cary,
NC, USA, release 9.2) were entered into a computer using
the double data entry technique with subsequent compari-
son of data sets and a plausibility check for missing values,
entry errors, and implausible entries.
Results
The study population included dogs in households in
Germany, France, and Spain. Overall, 176 flea-infested
households (115 treated with Bravecto™ (fluralaner) and 61
treated with Frontline™ (fipronil)) and 162 tick-infested
dogs (108 treated with Bravecto™ (fluralaner) and 54 with
Frontline™ (fipronil)) completed the study. Dogs had a
mean age of 4.6 years (range 10 weeks to 15 years) and a
mean body weight of 19.9 kg (range 2.2 to 59.8 kg); 46%
were males (13% of males were neutered) and 54% were
females (17% of females were neutered). Breeds represented
by more than ten dogs included: Great Anglo-French
Hound, English Setter, Spanish Greyhound, Brittany,
Beagle, Yorkshire Terrier, Dachshund, Fawn Brittany Basset,
Cavalier King Charles Spaniel, and Maltese. Additional
population characteristics were recorded (Table 1).
At baseline (day 0), the mean tick count/dog was
6.5 (range 1–57) and 6.1 (range 1–60) on dogs in the
Bravecto™ (fluralaner) and Frontline™ (fipronil) groups, re-
spectively. The most prevalent tick species identified at
baseline (day 0) were Rhipicephalus sanguineus group ticks
(34.8%), followed by Ixodes hexagonus (25.4%), Ixodes ricinus
(25.2%), Dermacentor reticulatus (9.6%), Ixodes spp. lar-
vae (4.0%), and Ixodes spp. nymphs (1.0%). The mean flea
count/household was 41.8 (range 0–254 per dog) and 38.1Table 2 Household flea infestations before treatment with Br
Germany
No. of HHs* No. of fleas (mean ± std) No. of HH
BravectoTM (fluralaner) 35 695 52
(19.9 ± 23.0)
FrontlineTM (fipronil) 17 261 27
(15.4 ± 17.2)
*HHs = households.(range 0–176 per dog) in the Bravecto™ (fluralaner) and
Frontline™ (fipronil) groups, respectively (Tables 2 and 3).
Flea-control efficacy in households was higher in
Bravecto™ (fluralaner) treated dogs and was 99.2% or
higher at all time points (Table 4). Tick-control efficacy on
individual dogs was higher in Bravecto™ (fluralaner)
treated dogs in weeks 2 and 4. In week 8, Frontline™
(fipronil) efficacy was slightly higher at 100% compared
with 99.7% for Bravecto™ (fluralaner). Both treatment
groups had a tick efficacy of 100% at week 12 (Table 5).
The percentage of households free of fleas (top of Table 6,
superiority with p < 0.025) was higher after Bravecto™ (flur-
alaner) treatment compared with Frontline™ (fipronil) treat-
ment at all time points. The percentage of households with
Bravecto™ (fluralaner) treated dogs that were free of ticks
was higher at all time points compared with households
with Frontline™ (fipronil)-treated dogs (bottom of Table 6,
non-inferiority with p < 0.0024) except for week 12 when
both groups were 100% free of ticks.
There were 35 (10.8%) Bravecto™ (fluralaner)-treated
dogs and 18 (11.7%) Frontline™ (fipronil)-treated dogs
with clinical signs of FAD at inclusion in the study. Inavecto™ (fluralaner) or Frontline™ (fipronil)
France Spain
s* No. of fleas (mean ± std) No. of HHs* No. of fleas (mean ± std)
3056 28 1059
(58.8 ± 92.7) (37.8 ± 38.2)
1280 17 783
(47.4 ± 59.2) (46.1 ± 44.0)
Table 3 Dog tick infestations before treatment with Bravecto™ (fluralaner) or Frontline™ (fipronil)
Germany France Spain
No. of dogs No. of ticks (mean ± std) No. of dogs No. of ticks (mean ± std) No. of dogs No. of ticks (mean ± std)
BravectoTM (fluralaner) 26 186 16 164 66 353
(7.2 ± 8.3) (10.3 ± 16.7) (5.3 ± 2.9)
FrontlineTM (fipronil) 13 73 11 98 30 160
(5.6 ± 7.9) (8.9 ± 17.4) (5.3 ± 3.1)
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these dogs were evaluated at each time point as showing
no clinical signs of FAD until the end of the study, while
in the Frontline™ (fipronil) group, only 55.6% (10 of 18)
had no clinical signs of FAD.
Overall, 8 adverse events reported during the entire
study period of 12 weeks were considered to be possibly
related to the administered treatment, with 4 reported
in each treatment group despite the 1:2 allocation ratio.
There were 2 dogs (0.5%) with vomiting/diarrhea and 2
dogs (0.5%) with appetite loss among the 383 dogs in
the Bravecto™ (fluralaner)-treated group; all of these
dogs recovered from their clinical signs and remained
in the study. In the 178 Frontline™ (fipronil)-treated
dogs, 3 dogs (1.7%) developed alopecia and crusts in
the dorsal lumbo-sacral area and 1 dog (0.6%) developed
intense pruritus. All of these dogs remained in the
study; 3 recovered and 1 had ongoing clinical signs at
the conclusion of the study.
Discussion
A single orally administered Bravecto™ (fluralaner) treat-
ment at the recommended dose effectively controlled flea
and tick infestations in client-owned dogs for 12 weeks
under natural infestation challenge. Bravecto™ (fluralaner) is
the first orally administered ectoparasiticide to demonstrate
this extended period of efficacy against both fleas and ticks
on dogs following a single dose. A single Bravecto™ (flurala-
ner) treatment was significantly non-inferior to 3 sequen-
tial Frontline™ (fipronil) treatments for controlling fleas
and ticks on dogs, as shown by the lower 97.5% confi-
dence limit > −0.15 at all time points (Table 6). Further-
more, Bravecto™ (fluralaner) treatment was demonstrated
to be superior to Frontline™ (fipronil) treatment in the
percentage of flea-free households in the study, as shown
by the lower 97.5% confidence limit > 0 at all time pointsTable 4 Flea control efficacy calculated using household
flea counts
BravectoTM (fluralaner) FrontlineTM (fipronil)
Week 2 99.2% 94.1%
Week 4 99.8% 93.0%
Week 8 99.8% 96.0%
Week 12 99.9% 97.3%(Table 6). Therefore, these efficacy results are consistent
with previously reported in vitro comparative insect neur-
onal membrane receptor binding results reported for flura-
laner and fipronil [5].
Bravecto™ (fluralaner) posted higher results for flea-
control efficacy at every time point (Table 4) and for tick-
control efficacy at every time point except for weeks 8 and
12, where the result was close to 100% for both treatments
(Table 5). The tick efficacy of Bravecto™ (fluralaner)
remained close to 100% over the entire 12 week study
period. This is a unique duration of effect for a single
orally administered acaricide.
A concern of veterinarians in clinical practice is patient
safety for new treatments. Considering the entire study
period of 12 weeks, only 4 of the 383 (1.0%) Bravecto™ (flur-
alaner)-treated dogs in the study had an adverse event and
these were exclusively transient gastrointestinal-related
events including vomiting and appetite loss. The 178
Frontline™ (fipronil)-treated dogs also had 4 adverse
events (2.2%) that were primarily dermal, as might be
expected with a topical treatment.
Poor compliance rates with required monthly retreatment
protocols for existing ectoparasite therapeutic options
are a potential factor in observed reduced ectoparasite
treatment efficacy [2]. Bravecto™ (fluralaner) is effective
over a 12 week retreatment interval compared to a standard
monthly treatment. There is no need to retreat with
Bravecto™ (fluralaner), which therefore should offer
increased compliance compared with recommended
monthly treatments.
Bravecto™ (fluralaner)-treated dogs demonstrated a very
strong recovery rate from clinical signs of FAD, with 85.7%
of these dogs showing immediate resolution of all clinical
signs compared with their skin lesions on entry into
the study. Although fleas must feed to be exposed to
systemic Bravecto™ (fluralaner) treatment, the degreeTable 5 Tick control efficacy calculated using tick counts
on individual dogs
BravectoTM (fluralaner) FrontlineTM (fipronil)
Week 2 99.9% 97.6%
Week 4 99.9% 93.8%
Week 8 99.7% 100%
Week 12 100% 100%





p value Lower 97.5%
1-sided C.I.a
Fleas
Week 2 89.57% 62.30% <0.0001 0.1498
Week 4 94.87% 63.93% <0.0001 0.1916
Week 8 95.65% 70.49% <0.0001 0.1416
Week 12 97.39% 81.97% <0.0001 0.0586
Ticks
Week 2 97.67% 89.47% 0.0006 −0.0575
Week 4 97.67% 84.21% 0.0001 −0.0175
Week 8 97.67% 94.74% 0.0024 −0.0953
Week 12 100.0% 100.0% n/ab n/ab
aResult greater than −0.15 required to declare significant non-inferiority. Result
greater than 0 required to declare significant one-sided superiority with
α = 0.025.
bNo statistical test as all households were free of ticks at week 12.
n/a: not applicable.
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of clinical signs of FAD at a higher rate than observed
with topical Frontline™ (fipronil) treatment.
Conclusions
A single oral dose of Bravecto™ (fluralaner) administered
to dogs in a chewable tablet is highly effective for 12 weeks
against naturally acquired flea and tick infestations on
client-owned dogs under field conditions. A single oral
dose of Bravecto™ (fluralaner) is significantly non-
inferior (ticks) and superior (fleas) to three doses of topical
Frontline™ (fipronil) administered over the same period.
Bravecto™ (fluralaner) is safe and well tolerated and the dur-
ation of activity offers a more convenient treatment over
monthly flea and tick control treatments with a potential
compliance advantage.
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